Cover Image

Combination lenvatinib plus pembrolizumab in the treatment of ovarian clear cell carcinoma: A case series

Effective second-line treatment options for patients with recurrent ovarian clear cell carcinoma (OCCC) are limited. This case series sought to report tumor characteristics and oncologic outcomes in a small group of patients treated with combination lenvatinib and pembrolizumab.A retrospective analy...

Full description

Saved in:

Bibliographic Details
Main Authors:	Corinne A. Calo (Author), Monica D. Levine (Author), Morgan D. Brown (Author), David M. O'Malley (Author), Floor J. Backes (Author)
Format:	Book
Published:	Elsevier, 2023-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Pembrolizumab and lenvatinib in recurrent ovarian clear cell carcinoma resistant to chemotherapy
by: Blair McNamara, et al.
Published: (2023)

Lenvatinib plus pembrolizumab in patients with advanced or recurrent uterine carcinosarcoma
by: Jonathan T. Hunt, et al.
Published: (2021)

The efficacy and safety of lenvatinib plus pembrolizumab therapy in patients with uterine carcinosarcoma
by: Risako Ozawa, et al.
Published: (2024)

Pembrolizumab with bevacizumab and cyclophosphamide for the treatment of recurrent ovarian clear cell carcinoma: A case series
by: Shannon M. Glynn, et al.
Published: (2024)

1 Examining the immune tumor microenvironment of endometrial cancer patients treated with pembrolizumab plus lenvatinib
by: Erica V. Carballo, et al.
Published: (2023)

Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab
by: Nicoletta Colombo, et al.
Published: (2023)

Lenvatinib and pembrolizumab in patients with advanced uterine cancer
by: A. G. Kedrova, et al.
Published: (2021)

Radiation recall dermatitis during treatment of endometrial cancer with pembrolizumab plus lenvatinib: A case report
by: Elise Heisler, et al.
Published: (2023)

Response to lenvatinib and pembrolizumab combination therapy in pembrolizumab-pretreated relapsed endometrial cancer
by: Kaito Mimura, et al.
Published: (2022)

Lenvatinib Plus Pembrolizumab vs. Chemotherapy in Pretreated Patients With Advanced Endometrial Cancer: A Cost-Effectiveness Analysis
by: Mingyang Feng, et al.
Published: (2022)

A case of pembrolizumab and lenvatinib as an alterntive therapy for leiomyosarcoma
by: Naaman Mehta, et al.
Published: (2023)

Activity of pembrolizumab and lenvatinib in mismatch repair deficient (dMMR) endometrial cancer patients who have failed pembrolizumab monotherapy: A case series
by: Peter G. Rose, et al.
Published: (2023)

Cost-effectiveness analysis of lenvatinib plus pembrolizumab compared with chemotherapy for patients with previously treated mismatch repair proficient advanced endometrial cancer in China
by: Zhiwei Zheng, et al.
Published: (2022)

Comparison of atezolizumab plus bevacizumab and lenvatinib for hepatocellular carcinoma with portal vein tumor thrombosis
by: Jeayeon Park, et al.
Published: (2024)

Esophagitis as a complication of the combination of lenvatinib and pembrolizumab for advanced endometrial cancer: A case report
by: Massine Fellouah, et al.
Published: (2023)

Sustained response to lenvatinib and pembrolizumab in two patients with KRAS-mutated endometrial mesonephric-like adenocarcinoma
by: Sherry Shen, et al.
Published: (2021)

Radiotherapy plus lenvatinib versus radiotherapy plus sorafenib for hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study
by: Min Zhang, et al.
Published: (2024)

Efficacy and safety of lenvatinib and pembrolizumab in the treatment of endometrial cancer: data from routine clinical practice in Russia
by: A. A. Rumyantsev, et al.
Published: (2024)

Treatment results and prognostic factors of clear cell ovarian carcinomas and ovarian carcinomas with clear cell component
by: M. D. Ahmedova, et al.
Published: (2014)

Comprehensive Treatment of Trans-Arterial Chemoembolization Plus Lenvatinib Followed by Camrelizumab for Advanced Hepatocellular Carcinoma Patients
by: Juanfang Liu, et al.
Published: (2021)

Lenvatinib and pembrolizumab versus platinum doublet chemotherapy as second-line therapy for advanced or recurrent endometrial cancer
by: Yutaka Yoneoka, et al.
Published: (2024)

A complete durable response of vaginal clear cell carcinoma with pembrolizumab: A case report
by: Hector S. Porragas-Paseiro, et al.
Published: (2023)

Case Series and a Literature Review: Two Ovarian Clear Cell Carcinoma Cases with Recurrent Endometriosis
by: Yin D, et al.
Published: (2023)

Combination of pembrolizumab and lenvatinib in second-line therapy for MSS/pMMR advanced endometrial cancer: literature review and a case report
by: A. D. Darenskaya, et al.
Published: (2024)

Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus
by: Uksha Saini, et al.
Published: (2022)

Durable partial response to pembrolizumab, lenvatinib, and letrozole in a case of recurrent uterine carcinosarcoma with ESR1 gene amplification
by: Jenny L. Soiffer, et al.
Published: (2024)

Complete remission of heavily treated ovarian clear cell carcinoma with ARID1A mutations after pembrolizumab and bevacizumab combination therapy: a case report
by: Yu-Chien Lin, et al.
Published: (2020)

Correction: Targeting TMEM205 mediated drug resistance in ovarian clear cell carcinoma using oncolytic virus
by: Uksha Saini, et al.
Published: (2023)

Lenvatinib for Hepatocellular Carcinoma: A Literature Review
by: Takeshi Hatanaka, et al.
Published: (2021)

The role of lenvatinib in the era of immunotherapy of hepatocellular carcinoma
by: Matthew Man Pok Lee, et al.
Published: (2023)

Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report
by: Yoichi Nishii, et al.
Published: (2022)

Chapter Demographic and Clinical Characteristics of Mucinous Epithelial Ovarian Cancer, and Survival Following a Mucinous Epithelial Ovarian Cancer Diagnosis
by: O'Malley, Cynthia D.
Published: (2013)

Chapter Demographic and Clinical Characteristics of Mucinous Epithelial Ovarian Cancer, and Survival Following a Mucinous Epithelial Ovarian Cancer Diagnosis
by: O'Malley, Cynthia D.
Published: (2013)

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma
by: Ting Zhou, et al.
Published: (2022)

Ovarian clear cell carcinoma with uterine intramural recurrence: Case report of ovarian clear cell carcinoma with fertility sparing treatment
by: Ting Yu Chang, et al.
Published: (2024)

Pembrolizumab-induced cytokine release syndrome with severe encephalopathy in the setting of clear cell vaginal carcinoma: A case report
by: Samantha Metzger, et al.
Published: (2024)

Lenvatinib Plus PD-1 Inhibitors versus Regorafenib in Patients with Advanced Hepatocellular Carcinoma After the Failure of Sorafenib: A Retrospective Study
by: Xu Y, et al.
Published: (2023)

Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis
by: Cheng Huang, et al.
Published: (2021)

SOX17 expression in ovarian clear cell carcinoma
by: Daichi Kodama, et al.
Published: (2024)

Antioxidants and Therapeutic Targets in Ovarian Clear Cell Carcinoma
by: Tsukuru Amano, et al.
Published: (2021)